JP2020521117A - 診断用終末糖化産物抗体 - Google Patents

診断用終末糖化産物抗体 Download PDF

Info

Publication number
JP2020521117A
JP2020521117A JP2019560086A JP2019560086A JP2020521117A JP 2020521117 A JP2020521117 A JP 2020521117A JP 2019560086 A JP2019560086 A JP 2019560086A JP 2019560086 A JP2019560086 A JP 2019560086A JP 2020521117 A JP2020521117 A JP 2020521117A
Authority
JP
Japan
Prior art keywords
age
cells
patient
sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521117A5 (enExample
Inventor
ルイス エス． グルバー
ルイス エス． グルバー
Original Assignee
シワ コーポレーション
シワ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シワ コーポレーション, シワ コーポレーション filed Critical シワ コーポレーション
Publication of JP2020521117A publication Critical patent/JP2020521117A/ja
Publication of JP2020521117A5 publication Critical patent/JP2020521117A5/ja
Priority to JP2023064753A priority Critical patent/JP2023098996A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019560086A 2017-05-04 2018-05-03 診断用終末糖化産物抗体 Pending JP2020521117A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023064753A JP2023098996A (ja) 2017-05-04 2023-04-12 診断用終末糖化産物抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US62/501,424 2017-05-04
US201762610003P 2017-12-22 2017-12-22
US62/610,003 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023064753A Division JP2023098996A (ja) 2017-05-04 2023-04-12 診断用終末糖化産物抗体

Publications (2)

Publication Number Publication Date
JP2020521117A true JP2020521117A (ja) 2020-07-16
JP2020521117A5 JP2020521117A5 (enExample) 2021-06-17

Family

ID=62223287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560086A Pending JP2020521117A (ja) 2017-05-04 2018-05-03 診断用終末糖化産物抗体
JP2023064753A Pending JP2023098996A (ja) 2017-05-04 2023-04-12 診断用終末糖化産物抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023064753A Pending JP2023098996A (ja) 2017-05-04 2023-04-12 診断用終末糖化産物抗体

Country Status (9)

Country Link
US (1) US20200150131A1 (enExample)
EP (1) EP3619540A1 (enExample)
JP (2) JP2020521117A (enExample)
KR (2) KR20200003067A (enExample)
CN (1) CN110832327A (enExample)
AU (1) AU2018261622A1 (enExample)
CA (1) CA3062082A1 (enExample)
IL (1) IL270285B2 (enExample)
WO (1) WO2018204679A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514580A (ja) * 2021-04-09 2024-04-02 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
IL251210B2 (en) 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
PL3337829T3 (pl) 2016-02-19 2020-05-18 Siwa Corporation Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE)
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020023532A1 (en) * 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
WO2021113152A1 (en) * 2019-12-02 2021-06-10 Viome, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
CA3177449A1 (en) 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003160599A (ja) * 2001-11-22 2003-06-03 Transgenic Inc カルボキシメチル化ペプチドに対する抗体
US20110319499A1 (en) * 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
JP2013533766A (ja) * 2010-06-18 2013-08-29 ディアフノプティクス ホールディング ベー．フェー． 皮膚組織の自己蛍光値を求めるための方法および装置
WO2016040752A1 (en) * 2014-09-12 2016-03-17 The Procter & Gamble Company Anti-aging skin care compositions and regimens
US20160215043A1 (en) * 2014-12-18 2016-07-28 Siwa Corporation Product and method for treating sarcopenia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
BRPI0913047A2 (pt) 2008-05-23 2013-03-05 Siwa Corp anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
EP3099380B1 (en) * 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
MA42979A (fr) * 2015-10-13 2021-05-26 Siwa Corp Anticorps anti-age et procédés d'utilisation correspondants
PL3337829T3 (pl) 2016-02-19 2020-05-18 Siwa Corporation Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003160599A (ja) * 2001-11-22 2003-06-03 Transgenic Inc カルボキシメチル化ペプチドに対する抗体
US20110319499A1 (en) * 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
JP2013533766A (ja) * 2010-06-18 2013-08-29 ディアフノプティクス ホールディング ベー．フェー． 皮膚組織の自己蛍光値を求めるための方法および装置
WO2016040752A1 (en) * 2014-09-12 2016-03-17 The Procter & Gamble Company Anti-aging skin care compositions and regimens
US20160215043A1 (en) * 2014-12-18 2016-07-28 Siwa Corporation Product and method for treating sarcopenia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KRTOLICA, A. ET AL.: "Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and ag", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 98, no. 21, JPN6022051418, 9 October 2001 (2001-10-09), pages 12072 - 12077, ISSN: 0004941517 *
MEERWALDT, R. ET AL.: "Skin autofluorescence is a strong predictor of cardiac mortality in diabetes", DIABETES CARE, vol. 30, no. 1, JPN6022051419, January 2007 (2007-01-01), pages 107 - 112, ISSN: 0004941518 *
NI JIAQIAN ET AL.: "Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for Age-related Macular Degeneration", MOLECULAR & CELLULAR PROTEOMICS, vol. 8, JPN6020015471, 2009, pages 1921 - 1933, ISSN: 0004731615 *
SCHALKWIJK CASPER G. ET AL.: "Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in hearts of diabetic", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1636, JPN6020015472, March 2004 (2004-03-01), pages 82 - 89, ISSN: 0004941515 *
SCHLEICHER ERWIN D. ET AL.: "Increased Accumulation of the Glycoxidation Product Nε-(carboxymethyl)lysine in Human Tissues in Di", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 99, no. 3, JPN6022010410, February 1997 (1997-02-01), pages 457 - 468, ISSN: 0004941516 *
VAN HEIJST, JEROEN W. J. ET AL., ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1043, no. 1, JPN6020008356, June 2005 (2005-06-01), pages 725 - 733, ISSN: 0004731616 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514580A (ja) * 2021-04-09 2024-04-02 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー
JP7607149B2 (ja) 2021-04-09 2024-12-26 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー

Also Published As

Publication number Publication date
EP3619540A1 (en) 2020-03-11
US20200150131A1 (en) 2020-05-14
JP2023098996A (ja) 2023-07-11
IL270285A (en) 2019-12-31
KR20200003067A (ko) 2020-01-08
CA3062082A1 (en) 2018-11-08
IL270285B1 (en) 2025-02-01
AU2018261622A1 (en) 2019-12-12
RU2019139256A3 (enExample) 2022-01-18
CN110832327A (zh) 2020-02-21
IL270285B2 (en) 2025-06-01
KR20240006702A (ko) 2024-01-15
RU2019139256A (ru) 2021-06-07
WO2018204679A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
JP2023098996A (ja) 診断用終末糖化産物抗体
US20240426842A1 (en) Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
JP7379165B2 (ja) Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
CN110546513A (zh) 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
JP6588893B2 (ja) 卵巣がんの自己抗体バイオマーカー
JP5607719B2 (ja) 代謝プロファイル
JP2023058524A (ja) 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体
JP6639408B2 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
JP7773526B2 (ja) 新規α－シンヌクレイン結合抗体又はその抗原結合部分
KR20210122813A (ko) 항체 및 그의 기능성 단편
JP2010181403A (ja) ガンの検出方法とそれに使用されるキット
CN120188044A (zh) 用于区分轻度创伤性脑损伤与超轻度创伤性脑损伤的生物标志物和方法
CN118715440A (zh) 诊断脑损伤的方法和系统
HK40036125A (en) Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
HK40020584A (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis
HK40015192A (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221212